News | November 06, 2008

Atherotech to Exhibit VAP Cholesterol Test at AHA 2008

November 7, 2008 - Atherotech Inc. announced it will be exhibiting its VAP Cholesterol Test at the American Heart Association Scientific Sessions 2008, Nov. 8-12 in New Orleans.
The VAP (vertical auto profile) Test is reportedly the only commercially available advanced lipid profile that routinely reports all three lipoprotein parameters - LDL, non-HDL and apoB - considered necessary by the 2008 expert consensus guidelines issued by the American Diabetes Association and American College of Cardiology. People with a family history or an existing condition of diabetes, high blood pressure or heart disease - or who are already taking cholesterol-lowering medication - are candidates for the comprehensive VAP Test.
The VAP Test reports all 15 lipoprotein measurements with a single test, and unlike other lipid profiles, it directly measures LDL and HDL and includes Lp(a) and apoB as part of its standard test. Atherotech has announced plans to add apolipoprotein A-1 (apoA1) to its reporting in early 2009. ApoA1 is the main component of protective HDL cholesterol and studies have shown that the apoB:apoA1 ratio may correlate better with increased risk of coronary artery disease (CAD) than total cholesterol and LDL:HDL ratio.
Atherotech said the VAP Cholesterol Test has been shown to identify significantly more patients with lipid abnormalities than the standard lipid panel (cholesterol and triglyceride test).
For more information: www.thevaptest.com

Related Content

Siemens Healthineers to Acquire Epocal from Alere
News | Point of Care Testing | July 26, 2017
Siemens Healthineers has entered into a definitive agreement to acquire Epocal Inc., a subsidiary of Alere Inc. Epocal...
Alere point of care POC testing for INR
News | Point of Care Testing | July 17, 2017 | Dave Fornell
July 17, 2017 — Despite issues with point-of-care INR testing company Alere Inc., Abbott announced this week it is on
Siemens Xprecia Stride anticoagulation, coagulation PT/INR or INR testing at the point of care (POC)

Point-of-care coagulation PT/INR testing with handheld devices can help improve outcomes with more convenient and frequent measurements to keep patients within the therapeutic range of anticoagulant agents.

Feature | Point of Care Testing | May 05, 2017 | Nicholas C. Vanderslice, Ph.D., and Arnol S. Rios
Point-of-care (POC) coagulation analyzers that measure prothrombin time/international normalized ratio (PT/INR) on fi
HyperMed Imaging, HyperView portable tissue oxygenation measurement system, FDA clearance
Technology | Point of Care Testing | January 27, 2017
HyperMed Imaging Inc. announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the...

The Xprecia Stride Coagulation Analyzer delivers fast, reliable prothrombin time/international normalized ratio (PT/INR) testing for point-of-care monitoring and management of oral anticoagulation therapy with warfarin, a vitamin K antagonist. It is the latest INR testing system to enter the market in late 2016. Read the article “Siemens Receives FDA Clearance of Xprecia Stride Coagulation Analyzer.”
 

 

Feature | Point of Care Testing | December 30, 2016 | Ravi Chawat
Point of care testing devices are gaining widespread approval for prompt medical diagnoses, especially in cardiology
INRatio, Alere, Abbott, I and R testing, INR testing
Feature | Point of Care Testing | December 07, 2016
December 7, 2016 — Abbott has filed a complaint to terminate its proposed acquisition of Alere based on the substanti
Siemens, FDA clearance, Xprecia Stride Coagulation Analyzer, point-of-care testing
Technology | Point of Care Testing | November 10, 2016
Siemens Healthineers announced U.S. Food and Drug Administration (FDA) 510(k) clearance for a hand-held portable...
Abbott, Alere, acquisition, point of care diagnostics
News | Point of Care Testing | February 03, 2016
Abbott and Alere Inc. announced a definitive agreement for Abbott to acquire Alere. Under the terms of the agreement,...
News | Point of Care Testing | December 22, 2015
Trinity Biotech plc announced submission of its Meritas Point of Care Analyzer and Meritas cardiac troponin-I (cTnI)...
The Lancet results, Abbott ARCHITECT STAT High Sensitive Troponin-I test, rule out myocardial infarction, Accident and Emergency, A&E
News | Point of Care Testing | October 13, 2015
The Lancet published results online that show Abbott’s ARCHITECT STAT High Sensitive Troponin-I (hsTnl) test may rule...
Overlay Init